In cardiovascular medicine, biomarker studies showing associations of higher IL-6 levels with higher cardiovascular disease incidence [8,[21], [22], [23]] and genetic studies [24], [25], [26] showing robust associations of an experimentally-validated [27] partial loss-of-function variant in the IL-6 receptor gene with protection against coronary disease have provided the evidence base for ongoing clinical trials that are evaluating the effects of IL-6 receptor inhibition in myocardial infarction. The gene discussed is IL6; the disease is coronary artery disorder.